论文部分内容阅读
目的:观察131碘(131I)治疗甲状腺功能亢进(甲亢)合并重症肝损害的效果。方法:选择甲亢合并重症肝损害20例,服用(240.5±111)MBq的131I,比较治疗前及治疗后3个月、6个月患者谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(AKP)及总胆红素(TB)水平,以及游离三碘甲状原氨酸(FT3)和游离甲状腺素(FT4)水平。结果:治疗3个月后,患者ALT、AST、AKP水平,以及FT3、FT4水平均非常显著低于治疗前(P<0.01);治疗6个月后,患者ALT、AST、AKP、TB水平均显著或非常显著低于治疗3个月时水平(P<0.05,P<0.01)。结论:131I治疗甲亢合并重症肝损害安全、有效。
Objective: To observe the effect of 131I treatment of hyperthyroidism (hyperthyroidism) complicated with severe liver damage. Methods: Twenty hyperthyroidism patients with severe liver injury were selected and 131I (240.5 ± 111) MBq was taken. The levels of ALT, AST and ALD were compared before and after treatment for 3 months and 6 months. Phosphatase (AKP) and total bilirubin (TB) levels, as well as free triiodothyronine (FT3) and free thyroxine (FT4) levels. Results: The levels of ALT, AST, AKP and the levels of FT3 and FT4 in patients after 3 months of treatment were significantly lower than those before treatment (P <0.01). After 6 months of treatment, the levels of ALT, AST, AKP and TB Significantly or very significantly lower than the level of 3 months after treatment (P <0.05, P <0.01). Conclusion: 131I is safe and effective in treating hyperthyroidism complicated with severe liver damage.